Analysts See $0.12 EPS for Simulations Plus, Inc. (SLP)

June 14, 2018 - By Kurt Siggers

Simulations Plus, Inc. (NASDAQ:SLP) LogoInvestors sentiment decreased to 1.5 in 2018 Q1. Its down 0.06, from 1.56 in 2017Q4. It worsened, as 5 investors sold Simulations Plus, Inc. shares while 21 reduced holdings. 12 funds opened positions while 27 raised stakes. 5.63 million shares or 2.37% more from 5.50 million shares in 2017Q4 were reported.
American Group holds 6,991 shares. State Bank Of America Corp De reported 0% stake. Citigroup owns 0% invested in Simulations Plus, Inc. (NASDAQ:SLP) for 11,670 shares. Stanley reported 61,773 shares stake. Cadence Capital Mgmt Lc holds 129,215 shares or 0.12% of its portfolio. Signaturefd Limited Liability Corp accumulated 39 shares or 0% of the stock. Morgan Stanley accumulated 36,256 shares. State Street reported 0% of its portfolio in Simulations Plus, Inc. (NASDAQ:SLP). Pnc Finance Services Grp holds 23,028 shares. Legal General Public Limited Liability accumulated 2,134 shares or 0% of the stock. Envestnet Asset Management invested 0% in Simulations Plus, Inc. (NASDAQ:SLP). Moreover, First Quadrant Limited Partnership Ca has 0% invested in Simulations Plus, Inc. (NASDAQ:SLP). Meeder Asset Mngmt holds 0% of its portfolio in Simulations Plus, Inc. (NASDAQ:SLP) for 353 shares. Jpmorgan Chase & Com has invested 0% in Simulations Plus, Inc. (NASDAQ:SLP). Wedge Capital Management L Ltd Partnership Nc reported 45,500 shares.

Since February 26, 2018, it had 0 insider purchases, and 5 insider sales for $1.29 million activity. KNEISEL JOHN ROBERT also sold $52,766 worth of Simulations Plus, Inc. (NASDAQ:SLP) on Friday, April 20.

Analysts expect Simulations Plus, Inc. (NASDAQ:SLP) to report $0.12 EPS on July, 9.They anticipate $0.01 EPS change or 7.69 % from last quarter’s $0.13 EPS. SLP’s profit would be $2.08 million giving it 42.60 P/E if the $0.12 EPS is correct. After having $0.11 EPS previously, Simulations Plus, Inc.’s analysts see 9.09 % EPS growth. It closed at $20.45 lastly. It is down 69.10% since June 14, 2017 and is uptrending. It has outperformed by 56.53% the S&P500.

Simulations Plus, Inc. develops and sells drug discovery and development software for mechanistic modeling and simulation. The company has market cap of $354.32 million. The firm offers GastroPlus, which simulates the absorption, pharmacokinetics , and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It has a 43.42 P/E ratio. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry computer program, which takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studio and ADMET Predictor.

More news for Simulations Plus, Inc. (NASDAQ:SLP) were recently published by: Businesswire.com, which released: “Simulations Plus to Present at the 8th Annual LD Micro Invitational Investor Conference on June 5, 2018” on June 01, 2018. Businesswire.com‘s article titled: “Simulations Plus Releases GastroPlusâ„¢ Version 9.6” and published on May 23, 2018 is yet another important article.

Simulations Plus, Inc. (NASDAQ:SLP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: